Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.46 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.46 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.46 |
| ▸ | PRKACA | P17612 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | PRKX | P51817 | 2/20 | 0.46 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.46 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 8/20 | 0.42 |
| ▸ | ACE | P12821 | 5/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7460067 | 1.00 | MAPK1 (0.49) | MAPK1CYP3A4ROCK2ROCK1RPS6KA5 | |
| SCHEMBL7447017 | 0.92 | ROCK2 (0.46) | MAPK1CYP3A4ROCK2ROCK1RPS6KA5 | |
| SCHEMBL7447022 | 0.92 | ROCK2 (0.46) | MAPK1CYP3A4ROCK2ROCK1RPS6KA5 | |
| SCHEMBL7461335 | 0.92 | ROCK2 (0.46) | MAPK1CYP3A4ROCK2ROCK1RPS6KA5 | |
| SCHEMBL7456826 | 0.91 | MAPK1 (0.43) | MAPK1CYP3A4ROCK2ROCK1RPS6KA5 | |
| SCHEMBL7450521 | 0.91 | MAPK1 (0.43) | MAPK1CYP3A4ROCK2ROCK1RPS6KA5 | |
| SCHEMBL7451298 | 0.88 | CYP3A4 (0.44) | MAPK1CYP3A4ROCK2ROCK1RPS6KA5 | |
| SCHEMBL7451165 | 0.88 | CYP3A4 (0.44) | MAPK1CYP3A4ROCK2ROCK1RPS6KA5 | |
| SCHEMBL7449619 | 0.87 | MME (0.40) | MAPK1CYP3A4MMEMMEL1MEN1 | |
| SCHEMBL7449610 | 0.87 | MME (0.40) | MAPK1CYP3A4MMEMMEL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| US-6495699-B2 | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | AGOURON PHARMACEUTICALS INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | BENDER STEVEN L (US) | 2002-02-14 | — | — | US | disclosed |
| US-6306892-B1 | ENZYME INHIBITORS HETEROCYCLIC AMIDES | AGOURON PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6174915-B1 | FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY | AGOURON PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6008243-A | AN ENZYME INHIBITOR FOR PREVENTING THE DEGRADATION AND REMODELING OF CONNECTIVE TISSUES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0937042-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998017643-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | MMP9, MMP2, MMP3 | MAPK1 2565/4885CYP3A4 692/4885ROCK2 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.